Adenoviral targeting of gene expression to tumors

Cancer Gene Therapy

Volumn 17, Issue 6, 2010, Pages 375-386

  Hogg, R T ^a   Garcia, J A ^a   Gerard, R D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bioluminescence; Hypoxia; Imaging; Promoter; Transcription

Indexed keywords

ADENOVIRUS VECTOR;

ADENOVIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; FEMALE; FIBROSARCOMA; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAVENOUS; LUCIFERASES; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; TRANSGENES; TRANSPLANTATION, HETEROLOGOUS;

ADENOVIRIDAE;

EID: 77952545895     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.1     Document Type: Article

References (43)

1. Ocak I, Baluk P, Barrett T, McDonald DM, Choyke P. The biologic basis of in vivo angiogenesis imaging. Front Biosci 2007; 12: 3601-3616.
2. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5: 436-446.
3. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999; 247: 495-504.
4. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008; 14: 178-183.
5. Ahmed Z, Bicknell R. Angiogenic signalling pathways. Methods Mol Biol 2009; 467: 3-24.
6. Brahimi-Horn C, Pouyssegur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006; 93: E73-E80.
7. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-8109.
8. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-1079.
9. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 2006; 45: 355-361.
10. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004; 10(12 Pt 1): 4109-4117.
11. Mees C, Nemunaitis J, Senzer N. Transcription factors: their potential as targets for an individualized therapeutic approach to cancer. Cancer Gene Ther 2009; 16: 103-112.
12. Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment. APMIS 2008; 116: 695-715.
13. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90: 2812-2816. (Pubitemid 23113507)
14. Varley AW, Munford RS. Physiologically responsive gene therapy. Mol Med Today 1998; 4: 445-451.
15. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 1987; 7: 725-737.
16. Takebe Y, Seiki M, Fujisawa J, Hoy P, Yokota K, Arai K et al. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol 1988; 8: 466-472.
17. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004; 11: 740-747.
18. University of Michigan Vector Core [Web Site]. Available at: http://www.med.umich.edu/vcore/Plasmids/pACRSVpLpA(-) loxP-SSP.htm accessed on October 12. 2009.
19. Biggs III WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 1999; 96: 7421-7426.
20. Dioum EM, Clarke SL, Ding K, Repa JJ, Garcia JA. HIF-2alpha- haploinsufficient mice have blunted retinal neovascularization due to impaired expression of a proangiogenic gene battery. Invest Ophthalmol Vis Sci 2008; 49: 2714-2720.
21. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 2009; 324: 1289-1293.
22. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ et al. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1\/\mice. Nat Genet 2003; 35: 331-340.
23. Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences. J Biol Chem 1988; 263: 9129-9141.
24. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-5454.
25. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11: 72-82.
26. McKnight SL, Gavis ER, Kingsbury R, Axel R. Analysis of transcriptional regulatory signals of the HSV thymidine kinase gene: identification of an upstream control region. Cell 1981; 25: 385-398.
27. Parsons WJ, Richardson JA, Graves KH, Williams RS, Moreadith RW. Gradients of transgene expression directed by the human myoglobin promoter in the developing mouse heart. Proc Natl Acad Sci USA 1993; 90: 1726-1730.
28. Aoki K, Barker C, Danthinne X, Imperiale MJ, Nabel GJ. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol Med 1999; 5: 224-231.
29. Gerard RD, Meidell RS In: Hames BD, Glover D (eds). Adenovirus Vectors in DNA Cloning-A Practical Approach: Mammalian Systems. Oxford University Press: Oxford, 1995, pp 285-307.
30. Varley AW, Coulthard MG, Meidell RS, Gerard RD, Munford RS. Inflammation-induced recombinant protein expression in vivo using promoters from acute-phase protein genes. Proc Natl Acad Sci USA 1995; 92: 5346-5350.
31. Garnett CT, Pao CI, Gooding LR. Detection and quantitation of subgroup C adenovirus DNA in human tissue samples by real-time PCR. Methods Mol Med 2007; 130: 193-204.
32. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2008. ISBN 3-900051-07-0 http://www.R-project.org.
33. Wisse E, Jacobs F, Topal B, Frederik P, De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther 2008; 15: 1193-1199.
34. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 2008; 105: 5483-5488.
35. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.
36. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006; 25: 6758-6780.
37. DeMeritt IB, Milford LE, Yurochko AD. Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. J Virol 2004; 78: 4498-4507.
38. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003; 10: 935-940.
39. Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther 2000; 7: 896-902.
40. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004; 10: 8603-8612.
41. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S et al. Hypoxia-mediated tumour targeting. Gene Ther 2003; 10: 540-549.
42. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002; 17: 56-61.
43. Praus M, Wauterickx K, Collen D, Gerard RD. Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther 1999; 6: 227-236.